Product Protocols: DGCR8 antibody tested with Human Hela Cells (ARP40984_P050)

Aviva Systems Biology is the original manufacturer of this DGCR8 antibody (ARP40984_P050)

Click here to view the DGCR8 antibody Western Blot Protocol

Product Datasheet Link: DGCR8 antibody (ARP40984_P050)

WB Suggested Anti-DGCR8 Antibody Titration: 0.2-1 ug/ml
ELISA Titer: 1:312500
Positive Control: Hela

Western Blot image:

Description of Target: DGCR8 contains 2 DRBM (double-stranded RNA-binding) domains and 1 WW domain. It may play a part in the etiology of the velocardiofacial/DiGeorge syndrome (VCFS/DGS), a developmental disorder characterized by structural and functional palate anomalies, conotruncal cardiac malformations, immunodeficiency, hypocalcemia, and typical facial anomalies.

Questions pertaining to this data can be directed to

Aviva Systems Biology’s DGCR8 antibody (ARP40984_P050) has been tested using other cell lysates and tissues. To obtain more data about this antibody please email us at

To order by phone call us at (888) 880-0001, fax us at (858) 552-6975 or send an email to Aviva manufactures this antibody so we can offer the best price. Please contact us to request pricing information.

All of Aviva’s products are guaranteed for the applications and experimental sample types mentioned in the datasheet below. Are you curious if this product will work for you? Please contact us at

This entry was posted in Western Blot Protocols and tagged , , , , , , . Bookmark the permalink.

Leave a Reply